- Home
- RDVT vs TBPH Comparison
RDVT vs TBPH Comparison
Compare RDVT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- TBPH
- Stock Information
- Founded
- RDVT 2017
- TBPH 2013
- Country
- RDVT United States
- TBPH United States
- Employees
- RDVT N/A
- TBPH N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- TBPH Health Care
- Exchange
- RDVT Nasdaq
- TBPH Nasdaq
- Market Cap
- RDVT 503.6M
- TBPH 464.5M
- IPO Year
- RDVT N/A
- TBPH N/A
- Fundamental
- Price
- RDVT $45.47
- TBPH $9.06
- Analyst Decision
- RDVT
- TBPH Buy
- Analyst Count
- RDVT 0
- TBPH 3
- Target Price
- RDVT N/A
- TBPH $11.33
- AVG Volume (30 Days)
- RDVT 103.1K
- TBPH 241.0K
- Earning Date
- RDVT 05-07-2025
- TBPH 05-08-2025
- Dividend Yield
- RDVT 0.64%
- TBPH N/A
- EPS Growth
- RDVT N/A
- TBPH N/A
- EPS
- RDVT 0.61
- TBPH N/A
- Revenue
- RDVT $79,681,000.00
- TBPH $64,381,000.00
- Revenue This Year
- RDVT $15.93
- TBPH $51.09
- Revenue Next Year
- RDVT $13.85
- TBPH N/A
- P/E Ratio
- RDVT $76.14
- TBPH N/A
- Revenue Growth
- RDVT 26.30
- TBPH 12.12
- 52 Week Low
- RDVT $19.41
- TBPH $7.44
- 52 Week High
- RDVT $46.85
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- RDVT 78.35
- TBPH 42.51
- Support Level
- RDVT $38.00
- TBPH $9.90
- Resistance Level
- RDVT $40.10
- TBPH $10.55
- Average True Range (ATR)
- RDVT 1.63
- TBPH 0.34
- MACD
- RDVT 0.93
- TBPH -0.01
- Stochastic Oscillator
- RDVT 97.79
- TBPH 10.49
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).